Ionis Pharmaceuticals, Inc.
IONS
$43.03
$0.050.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 243.47% | -41.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 243.47% | -41.91% | |||
| Cost of Revenue | 13.69% | -21.82% | |||
| Gross Profit | 463.98% | -178.36% | |||
| SG&A Expenses | 8.46% | -5.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.12% | -17.47% | |||
| Operating Income | 195.20% | -32.52% | |||
| Income Before Tax | 184.14% | -37.17% | |||
| Income Tax Expenses | -117.24% | 104.31% | |||
| Earnings from Continuing Operations | 184.08% | -40.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 184.08% | -40.81% | |||
| EBIT | 195.20% | -32.52% | |||
| EBITDA | 199.05% | -33.23% | |||
| EPS Basic | 183.87% | -40.17% | |||
| Normalized Basic EPS | 197.81% | -37.85% | |||
| EPS Diluted | 175.62% | -40.17% | |||
| Normalized Diluted EPS | 185.36% | -37.85% | |||
| Average Basic Shares Outstanding | 0.25% | 0.47% | |||
| Average Diluted Shares Outstanding | 14.87% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||